Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x100px
Document › Details

Basilea Pharmaceutica Ltd.. (6/2/17). "Press Release: Basilea Names New Member of Its Extended Management Committee". Basel.

Organisations Organisation Basilea Pharmaceutica Ltd. (SIX: BSLN)
  Group Basilea (Group)
  Organisation 2 Novartis Pharma AG
  Group Novartis (Group)
Products Product antibiotic
  Product 2 cancer drug
Persons Person Heller, Damian (Basilea 201708– General Counsel + Corp Secretary joined 2015 before Novartis Pharma + Syngenta)
  Person 2 Scott, Ronald (Ron) (Basilea 201212–201804 CEO before COO before CFO RETIRED 2/18 proposed for Board)

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of August 1, 2017, Damian Heller will assume the role of General Counsel & Corporate Secretary and join the Extended Management Committee which reports to the CEO. Mr. Heller succeeds Elizabeth Rozek who will be leaving Basilea to relocate to the United States.

Mr. Heller joined Basilea in 2015 as Deputy General Counsel and Global Compliance Officer. Prior to joining Basilea, he served as Global Compliance Officer at Novartis Pharma AG, Corporate Secretary of Syngenta AG and Director of the Basel Institute on Governance.

Mr. Heller holds a master's degree in Law from the University of Basel and a master's degree in Business Administration from the University of Rochester, New York, USA.

Ronald Scott, Basilea's Chief Executive Officer, commented: "We are very pleased that Mr. Heller will assume the role of General Counsel & Corporate Secretary. Damian's knowledge and broad experience in all aspects of pharmaceutical industry law and compliance will be an asset to Basilea. Ms. Rozek joined Basilea as counsel in 2010 and has served as General Counsel & Corporate Secretary since 2011. We wish to sincerely thank Elizabeth for her commitment and valuable contributions to Basilea's success during these years."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address the medical problem of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Basilea (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top